Literature DB >> 19183912

[Therapeutic strategies for psoriasis and psoriatic arthritis].

G Wozel1.   

Abstract

Psoriasis is a chronic, immune-mediated inflammatory disorder with a genetic background, whose treatment is currently undergoing a paradigm shift. For many patients clinical signs and symptoms of psoriatic skin and joint disease are most important. From the public health perspective, however, recent findings that suggest a high degree of co-morbidity is becoming increasingly relevant. Because it is also highly significant from the patients' perspective, the improvement of health-related quality of life should be considered as the third treatment goal. Modern therapeutic concepts interact with specific pathogenetically relevant molecular targets. The development of such"targeted therapies" reflects our increasing understanding of the pathogenetic principles of psoriasis. Provided that the whole spectrum of approved remedies is employed as indicated, psoriasis has become a condition that is amenable to early intervention and can be treated effectively in the long run.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19183912     DOI: 10.1007/s00105-008-1662-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  33 in total

Review 1.  Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.

Authors:  Brian J Nickoloff; Frank O Nestle
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].

Authors:  B Manger; H Michels; H G Nüsslein; M Schneider; J Sieper
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

3.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

Review 4.  The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis.

Authors:  Jochen Schmitt; Gottfried Wozel
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

Review 5.  Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.

Authors:  Gillian C de Gannes; Mehran Ghoreishi; Janet Pope; Anthony Russell; David Bell; Stewart Adams; Kamran Shojania; Magdalena Martinka; Jan P Dutz
Journal:  Arch Dermatol       Date:  2007-02

Review 6.  Biology of tumor necrosis factor-alpha- implications for psoriasis.

Authors:  Arndt J G Schottelius; Lyle L Moldawer; Charles A Dinarello; Khusru Asadullah; Wolfram Sterry; Carl K Edwards
Journal:  Exp Dermatol       Date:  2004-04       Impact factor: 3.960

Review 7.  Dendritic cells--why can they help and hurt us.

Authors:  Knut Schäkel
Journal:  Exp Dermatol       Date:  2009-01-24       Impact factor: 3.960

8.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors:  Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

9.  Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.

Authors:  Daniel Creamer; Michael Allen; Rhys Jaggar; Richard Stevens; Roy Bicknell; Jonathan Barker
Journal:  Arch Dermatol       Date:  2002-06

Review 10.  Treatment goals in psoriasis.

Authors:  Kristian Reich; Ulrich Mrowietz
Journal:  J Dtsch Dermatol Ges       Date:  2007-07       Impact factor: 5.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.